表紙
市場調查報告書

免疫沉澱的全球市場預測 2024年:單獨免疫沉澱、共免疫沉澱法 (Co-IP) 、染色質免疫沉澱 (ChIP) 、RNA 免疫沈澱 (RIP)

Immunoprecipitation Market by Product (Kit, Reagent (Antibodies, Magnetic Buffer)), Type (Individual IP, Coimmunoprecipitation, CHIP), End User (Academics, Research Institutes, Pharmaceutical and Biotechnology Companies) - Global Forecast to 2024

出版商 MarketsandMarkets 商品編碼 790810
出版日期 內容資訊 英文 113 Pages
訂單完成後即時交付
價格
免疫沉澱的全球市場預測 2024年:單獨免疫沉澱、共免疫沉澱法 (Co-IP) 、染色質免疫沉澱 (ChIP) 、RNA 免疫沈澱 (RIP) Immunoprecipitation Market by Product (Kit, Reagent (Antibodies, Magnetic Buffer)), Type (Individual IP, Coimmunoprecipitation, CHIP), End User (Academics, Research Institutes, Pharmaceutical and Biotechnology Companies) - Global Forecast to 2024
出版日期: 2019年02月13日內容資訊: 英文 113 Pages
簡介

免疫沉澱市場預測將從2018年的5億6,000萬美元成長到2024年7億5,000萬美元的規模,在預測期間中預計將以5.0%的年複合成長率 (CAGR) 成長。該市場的成長,由於生命科學產業上研究活動數的增加及免疫疾病相關的抗原識別的需求高漲而受到促進。可是,蛋白質純化替代技術的存在,預計抑制今後數年的該市場的成長。

本報告提供全球免疫沉澱市場調查,市場概要,市場成長的各種影響因素及市場機會分析,各市場區隔、各地區/主要國家趨勢與市場規模的變化與預測,競爭環境,主要企業簡介等資訊彙整。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 免疫沉澱:市場概要
  • 免疫沉澱市場:各產品
  • 北美的免疫沉澱市場:各類型

第5章 市場概要

  • 簡介
  • 市場動態
    • 成長推動因素
    • 阻礙成長要素
    • 市場機會
    • 課題

第6章 免疫沉澱市場:各類型

  • 簡介
  • 單獨免疫沉澱
  • 共免疫沉澱法 (Co-IP)
  • 染色質免疫沉澱 (ChIP)
  • RNA 免疫沈澱 (RIP)

第7章 免疫沉澱市場:各產品

  • 簡介
  • 套件
  • 試劑
    • 抗體
  • 配件

第8章 免疫沉澱市場:各終端用戶

  • 簡介
  • 大學 & 研究機關
  • 醫藥品 & 生物科技企業
  • CRO

第9章 免疫沉澱市場:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
  • 亞太地區
  • 其他

第10章 競爭環境

  • 概要
  • 供應商的基準
  • 競爭領導製圖
  • 市場排行榜分析
  • 競爭情形、趨勢

第11章 企業簡介

  • THERMO FISHER SCIENTIFIC
  • ABCAM
  • GENSCRIPT
  • MERCK KGAA
  • BIO-RAD LABORATORIES
  • BIOLEGEND
  • TaKaRa BIO
  • ROCKLAND IMMUNOCHEMICALS
  • CELL SIGNALING TECHNOLOGY
  • GENO TECHNOLOGY

第12章 附錄

目錄
Product Code: BT 6910

"Increasing research activity in the life sciences industry is expected to drive the overall growth of the immunoprecipitation market."

The immunoprecipitation market is projected to reach USD 750 million by 2024 from USD 560 million in 2018, at CAGR of 5.0% during forecast period. The growth of this market is majorly driven by the increasing number of research activities in the life sciences industry and the growing need to identify antigens associated with autoimmune diseases (through antigen-antibody interaction to understand disease mechanisms and develop relevant drugs targeting these diseases). However, the presence of alternative technologies for protein purification is expected to restrain the growth of this market in the coming years.

"The kits segment is expected to grow at the highest CAGR during the forecast period."

The immunoprecipitation market, by product, has been categorized into three major segments- kits, reagents, and accessories. The kits segment is estimated to grow at the highest CAGR from 2018 to 2024. The need for repeat purchase of kits, coupled with the increasing number of IP assays to isolate and purify antigens, forms a major driver for the growth of this segment.

"The pharmaceutical & biotechnology companies segment is expected to grow at the highest CAGR during the forecast period."

The immunoprecipitation market, by end user, has been categorized into three major segments-academic & research institutes, pharmaceutical & biotechnology companies, and contract research organizations (CROs). The pharmaceutical & biotechnology companies segment is estimated to grow at the highest CAGR from 2018 to 2024. The increasing demand for protein-based drugs to drive the demand for immunoprecipitation in this end-user segment will support market growth.

"Asia Pacific projected to grow at the highest CAGR during the forecast period."

In the immunoprecipitation market, Asia Pacific is projected to record the highest growth during the forecast period. China, Japan, and India are the major markets for immunoprecipitation in the Asia Pacific. Increasing investments by governments and industries, growing biotechnology research in these regions, and rising awareness about personalized therapeutics are expected to drive the growth of these markets during the forecast period.

In-depth interviews were conducted with Chief Executive Officers (CEOs), marketing directors, other innovation and technology directors, and executives from various key organizations operating in the immunoprecipitation market.

  • By Company Type: Tier 1-48%, Tier 2-34%, and Tier 3-18%
  • By Designation: C-level Executives-42%, Directors-40%, and Others-18%
  • By Region: North America-38%, Europe-25%, APAC-30%, and RoW-7%

The immunoprecipitation market comprises major providers such as Thermo Fisher Scientific (US), Abcam (UK), Merck KGaA (Germany). The study includes an in-depth competitive analysis of these key players in the immunoprecipitation market, along with their company profiles, recent developments, and key market strategies.

Research Coverage:

The market study covers the immunoprecipitation market across various segments. It aims at estimating the market size and the growth potential of this market across different segments, on the basis of product, analyte type, product, end user, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants in this market and provide information on the closest approximations of the revenue numbers for the overall immunoprecipitation market and its subsegments. This report will help the stakeholders to understand the competitive landscape, to gain more insights to better position their businesses, and to plan suitable go-to-market strategies. The report will also help the stakeholders to understand the pulse of the market and provide information on key market drivers, restraints, and opportunities.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. STAKEHOLDERS
  • 1.6. LIMITATIONS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH APPROACH
    • 2.1.1. SECONDARY RESEARCH
      • 2.1.1.1. Key data from secondary sources
    • 2.1.2. PRIMARY RESEARCH
      • 2.1.2.1. Key data from primary sources
      • 2.1.2.2. Break down of primaries
      • 2.1.2.3. Key industry insights
  • 2.2. MARKET SIZE ESTIMATION
  • 2.3. DATA TRIANGULATION APPROACH
  • 2.4. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. IMMUNOPRECIPITATION: MARKET OVERVIEW
  • 4.2. IMMUNOPRECIPITATION MARKET, BY PRODUCT (2018-2024)
  • 4.3. NORTH AMERICA: IMMUNOPRECIPITATION MARKET, BY TYPE (2018)

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. MARKET DRIVERS
      • 5.2.1.1. Increasing number of life sciences research activities
      • 5.2.1.2. Growing need to identify antigens that are associated with autoimmune diseases
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. Presence of alternative technologies
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Increasing focus on biomarker discovery
    • 5.2.4. CHALLENGES
      • 5.2.4.1. Quality concerns over research antibodies

6. IMMUNOPRECIPITATION MARKET, BY TYPE

  • 6.1. INTRODUCTION
  • 6.2. INDIVIDUAL IMMUNOPRECIPITATION
    • 6.2.1. INCREASING DEMAND FOR BIOLOGICS IS DRIVING THE GROWTH OF THE MARKET
  • 6.3. CO-IMMUNOPRECIPITATION
    • 6.3.1. INCREASING USE OF CO-IP TO STUDY PROTEIN COMPLEXES FORMS A KEY MARKET DRIVER
  • 6.4. CHROMATIN IMMUNOPRECIPITATION
    • 6.4.1. GROWING ADOPTION OF HIGH-THROUGHPUT TECHNOLOGIES WILL CONTRIBUTE TO ADOPTION OF CHIP
  • 6.5. RNA IMMUNOPRECIPITATION
    • 6.5.1. AVAILABILITY OF GOVERNMENT FUNDING WILL DRIVE THE ADOPTION OF RIP KITS

7. IMMUNOPRECIPITATION MARKET, BY PRODUCT

  • 7.1. INTRODUCTION
  • 7.2. KITS
    • 7.2.1. KITS SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE IMMUNOPRECIPITATION MARKET DURING THE FORECAST PERIOD
  • 7.3. REAGENTS
    • 7.3.1. ANTIBODIES
      • 7.3.1.1. Antibodies, by type
        • 7.3.1.1.1. Primary Antibodies
        • 7.3.1.1.1.1. Primary antibodies to account for the largest share of the immunoprecipitation antibodies market during the forecast period
        • 7.3.1.1.2. Secondary Antibodies
        • 7.3.1.1.2.1. Low cost of production - A major factor driving the growth of the secondary antibodies market
    • 7.3.2. BEADS
      • 7.3.2.1. Beads, by type
      • 7.3.2.2. Agarose beads
        • 7.3.2.2.1. High binding capacity and lower cost - Factors supporting the wide use of agarose beads in research laboratories
      • 7.3.2.3. Magnetic beads
        • 7.3.2.3.1. Magnetic bead-based separation helps increase throughput and reduces hands-on time
      • 7.3.2.4. Buffers
        • 7.3.2.4.1. Buffer solutions play an important role in maintaining pH balance in IP assays
  • 7.4. ACCESSORIES

8. IMMUNOPRECIPITATION MARKET, BY END USER

  • 8.1. INTRODUCTION
  • 8.2. ACADEMIC & RESEARCH INSTITUTES
    • 8.2.1. ACADEMIC & RESEARCH INSTITUTES ARE THE LARGEST END USERS OF IMMUNOPRECIPITATION
  • 8.3. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 8.3.1. INCREASING DEMAND FOR PROTEIN-BASED DRUGS TO DRIVE THE DEMAND FOR IMMUNOPRECIPITATION IN THIS END-USER SEGMENT
  • 8.4. CONTRACT RESEARCH ORGANIZATIONS
    • 8.4.1. GROWTH IN OUTSOURCING OF PROTEIN PURIFICATION ACTIVITIES - A MAJOR FACTOR DRIVING THE DEMAND FOR IMMUNOPRECIPITATION TECHNOLOGIES IN CONTRACT RESEARCH ORGANIZATIONS

9. IMMUNOPRECIPITATION MARKET, BY REGION

  • 9.1. INTRODUCTION
  • 9.2. NORTH AMERICA
    • 9.2.1. US
      • 9.2.1.1. Growing research will drive market growth
    • 9.2.2. CANADA
      • 9.2.2.1. Increasing genomics and proteomics research to drive the adoption of immunoprecipitation in the coming years
  • 9.3. EUROPE
    • 9.3.1. GROWTH OF THE LIFE SCIENCES SECTOR WILL SUPPORT THE DEMAND FOR IMMUNOPRECIPITATION
  • 9.4. ASIA PACIFIC
    • 9.4.1. INCREASING DEMAND FOR NOVEL ANTIBODY AND PROTEIN-BASED DRUGS SUPPORT MARKET GROWTH IN THE ASIA PACIFIC
  • 9.5. REST OF THE WORLD

10. COMPETITIVE LANDSCAPE

  • 10.1. OVERVIEW
  • 10.2. VENDOR BENCHMARKING
  • 10.3. COMPETITIVE LEADERSHIP MAPPING
    • 10.3.1. VISIONARY LEADERS
    • 10.3.2. INNOVATORS
    • 10.3.3. DYNAMIC DIFFERENTIATORS
    • 10.3.4. EMERGING COMPANIES
  • 10.4. MARKET RANKING ANALYSIS, 2017
  • 10.5. COMPETITIVE SITUATION AND TRENDS
    • 10.5.1. EXPANSIONS
    • 10.5.2. COLLABORATIONS, PARTNERSHIPS, AND AGREEMENTS
    • 10.5.3. PRODUCT LAUNCHES
    • 10.5.4. ACQUISITIONS

11. COMPANY PROFILES (Business overview, Products offered, Recent Developments, MNM view)*

  • 11.1. THERMO FISHER SCIENTIFIC
  • 11.2. ABCAM
  • 11.3. GENSCRIPT
  • 11.4. MERCK KGAA
  • 11.5. BIO-RAD LABORATORIES
  • 11.6. BIOLEGEND
  • 11.7. TAKARA BIO
  • 11.8. ROCKLAND IMMUNOCHEMICALS
  • 11.9. CELL SIGNALING TECHNOLOGY
  • 11.10. GENO TECHNOLOGY

*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

12. APPENDIX

  • 12.1. DISCUSSION GUIDE
  • 12.2. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3. AVAILABLE CUSTOMIZATIONS
  • 12.4. RELATED REPORTS
  • 12.5. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: IMMUNOPRECIPITATION MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 2: INDIVIDUAL IMMUNOPRECIPITATION MARKET, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 3: NORTH AMERICA: INDIVIDUAL IMMUNOPRECIPITATION MARKET, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 4: CO-IMMUNOPRECIPITATION MARKET, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 5: NORTH AMERICA: CO-IMMUNOPRECIPITATION MARKET, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 6: CHROMATIN IMMUNOPRECIPITATION MARKET, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 7: NORTH AMERICA: CHROMATIN IMMUNOPRECIPITATION MARKET, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 8: RNA IMMUNOPRECIPITATION MARKET, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 9: NORTH AMERICA: RNA IMMUNOPRECIPITATION MARKET, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 10: IMMUNOPRECIPITATION MARKET, BY PRODUCT, 2016-2024 (USD MILLION)
  • TABLE 11: IMMUNOPRECIPITATION KITS MARKET, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 12: NORTH AMERICA: IMMUNOPRECIPITATION KITS MARKET, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 13: IMMUNOPRECIPITATION REAGENTS MARKET, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 14: NORTH AMERICA: IMMUNOPRECIPITATION REAGENTS MARKET, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 15: IMMUNOPRECIPITATION REAGENTS MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 16: IMMUNOPRECIPITATION ANTIBODIES MARKET, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 17: NORTH AMERICA: IMMUNOPRECIPITATION ANTIBODIES MARKET, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 18: IMMUNOPRECIPITATION ANTIBODIES MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 19: IMMUNOPRECIPITATION MARKET FOR PRIMARY ANTIBODIES, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 20: NORTH AMERICA: IMMUNOPRECIPITATION MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 21: IMMUNOPRECIPITATION MARKET FOR SECONDARY ANTIBODIES, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 22: NORTH AMERICA: IMMUNOPRECIPITATION MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 23: IMMUNOPRECIPITATION BEADS MARKET, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 24: NORTH AMERICA: IMMUNOPRECIPITATION BEADS MARKET, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 25: IMMUNOPRECIPITATION BEADS MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 26: IMMUNOPRECIPITATION MARKET FOR AGAROSE BEADS, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 27: NORTH AMERICA: IMMUNOPRECIPITATION MARKET FOR AGAROSE BEADS, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 28: IMMUNOPRECIPITATION MARKET FOR MAGNETIC BEADS, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 29: NORTH AMERICA: IMMUNOPRECIPITATION MARKET FOR MAGNETIC BEADS, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 30: IMMUNOPRECIPITATION BUFFERS MARKET, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 31: NORTH AMERICA: IMMUNOPRECIPITATION BUFFERS MARKET, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 32: IMMUNOPRECIPITATION ACCESSORIES MARKET, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 33: NORTH AMERICA: IMMUNOPRECIPITATION ACCESSORIES MARKET, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 34: IMMUNOPRECIPITATION MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 35: IMMUNOPRECIPITATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 36: NORTH AMERICA: IMMUNOPRECIPITATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 37: IMMUNOPRECIPITATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 38: NORTH AMERICA: IMMUNOPRECIPITATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 39: IMMUNOPRECIPITATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 40: NORTH AMERICA: IMMUNOPRECIPITATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 41: IMMUNOPRECIPITATION MARKET, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 42: NORTH AMERICA: IMMUNOPRECIPITATION MARKET, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 43: NORTH AMERICA: IMMUNOPRECIPITATION MARKET, BY PRODUCT, 2016-2024 (USD MILLION)
  • TABLE 44: NORTH AMERICA: IMMUNOPRECIPITATION REAGENTS MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 45: NORTH AMERICA: IMMUNOPRECIPITATION ANTIBODIES MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 46: NORTH AMERICA: IMMUNOPRECIPITATION BEADS MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 47: NORTH AMERICA: IMMUNOPRECIPITATION MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 48: NORTH AMERICA: IMMUNOPRECIPITATION MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 49: US: IMMUNOPRECIPITATION MARKET, BY PRODUCT, 2016-2024 (USD MILLION)
  • TABLE 50: US: IMMUNOPRECIPITATION REAGENTS MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 51: US: IMMUNOPRECIPITATION ANTIBODIES MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 52: US: IMMUNOPRECIPITATION BEADS MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 53: US: IMMUNOPRECIPITATION MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 54: US: IMMUNOPRECIPITATION MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 55: CANADA: IMMUNOPRECIPITATION MARKET, BY PRODUCT, 2016-2024 (USD MILLION)
  • TABLE 56: CANADA: IMMUNOPRECIPITATION REAGENTS MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 57: CANADA: IMMUNOPRECIPITATION ANTIBODIES MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 58: CANADA: IMMUNOPRECIPITATION BEADS MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 59: CANADA: IMMUNOPRECIPITATION MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 60: CANADA: IMMUNOPRECIPITATION MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 61: EUROPE: IMMUNOPRECIPITATION MARKET, BY PRODUCT, 2016-2024 (USD MILLION)
  • TABLE 62: EUROPE: IMMUNOPRECIPITATION REAGENTS MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 63: EUROPE: IMMUNOPRECIPITATION ANTIBODIES MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 64: EUROPE: IMMUNOPRECIPITATION BEADS MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 65: EUROPE: IMMUNOPRECIPITATION MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 66: EUROPE: IMMUNOPRECIPITATION MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 67: ASIA PACIFIC: IMMUNOPRECIPITATION MARKET, BY PRODUCT, 2016-2024 (USD MILLION)
  • TABLE 68: ASIA PACIFIC: IMMUNOPRECIPITATION REAGENTS MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 69: ASIA PACIFIC: IMMUNOPRECIPITATION ANTIBODIES MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 70: ASIA PACIFIC: IMMUNOPRECIPITATION BEADS MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 71: ASIA PACIFIC: IMMUNOPRECIPITATION MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 72: ASIA PACIFIC: IMMUNOPRECIPITATION MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 73: ROW: IMMUNOPRECIPITATION MARKET, BY PRODUCT, 2016-2024 (USD MILLION)
  • TABLE 74: ROW: IMMUNOPRECIPITATION REAGENTS MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 75: ROW: IMMUNOPRECIPITATION ANTIBODIES MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 76: ROW: IMMUNOPRECIPITATION BEADS MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 77: ROW: IMMUNOPRECIPITATION MARKET, BY TYPE, 2016-2024 (USD MILLION)
  • TABLE 78: ROW: IMMUNOPRECIPITATION MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 79: EXPANSIONS, 2016-2018
  • TABLE 80: COLLABORATIONS, PARTNERSHIPS, AND AGREEMENTS, 2016-2018
  • TABLE 81: PRODUCT LAUNCHES, 2016-2018
  • TABLE 82: ACQUISITIONS, 2016-2018

LIST OF FIGURES

  • FIGURE 1: IMMUNOPRECIPITATION MARKET
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATIONS, AND REGION
  • FIGURE 4: BOTTOM-UP APPROACH
  • FIGURE 5: TOP-DOWN APPROACH
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: IMMUNOPRECIPITATION MARKET, BY PRODUCT, 2018 VS. 2024 (USD MILLION)
  • FIGURE 8: IMMUNOPRECIPITATION MARKET, BY TYPE, 2018 VS. 2024 (USD MILLION)
  • FIGURE 9: IMMUNOPRECIPITATION MARKET, BY END USER, 2018 VS. 2024 (USD MILLION)
  • FIGURE 10: GEOGRAPHICAL SNAPSHOT OF THE IMMUNOPRECIPITATION MARKET
  • FIGURE 11: INCREASING NUMBER OF RESEARCH ACTIVITIES IN THE LIFE SCIENCES INDUSTRY IS A KEY DRIVER FOR THE IMMUNOPRECIPITATION MARKET
  • FIGURE 12: KITS TO CONTINUE TO DOMINATE THE IMMUNOPRECIPITATION MARKET IN 2024
  • FIGURE 13: INDIVIDUAL IP ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN IMMUNOPRECIPITATION MARKET IN 2018
  • FIGURE 14: IMMUNOPRECIPITATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 15: LIFE SCIENCES R&D SPENDING, GLOBAL VS. US (USD BILLION)
  • FIGURE 16: NORTH AMERICA: IMMUNOPRECIPITATION MARKET SNAPSHOT
  • FIGURE 17: ASIA PACIFIC: IMMUNOPRECIPITATION MARKET SNAPSHOT
  • FIGURE 18: IMMUNOPRECIPITATION MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING, 2017
  • FIGURE 19: RANK OF COMPANIES IN THE GLOBAL IMMUNOPRECIPITATION MARKET, 2017
  • FIGURE 20: THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
  • FIGURE 21: ABCAM: COMPANY SNAPSHOT
  • FIGURE 22: GENSCRIPT: COMPANY SNAPSHOT
  • FIGURE 23: MERCK KGAA: COMPANY SNAPSHOT
  • FIGURE 24: BIO-RAD LABORATORIES: COMPANY SNAPSHOT
  • FIGURE 25: TAKARA BIO: COMPANY SNAPSHOT